From Name:
From Email:
To Name:
To Email:

Optional Message:


Auranofin drug could improve prognosis for ovarian cancer patients exhibiting BRCA1 deficiency

from News-Medical

The anti-rheumatic drug auranofin is currently undergoing trials for repurposing to treat recurrent epithelial ovarian cancer, which makes up around 90 per cent of diagnosed ovarian cancers. Researchers publishing in Mutation Research: Fundamentals and Molecular Mechanisms of Mutagenesis used laboratory tests to demonstrate that treatment with auranofin can reduce the survival rates of cancerous cells exhibiting depleted levels of BRCA1 (breast cancer 1, early onset). more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063